Considerations for Older Adults in New Drug Development and Clinical Research
As the population ages,the need for medications tailored to older adults becomes increasingly critical.Due to pathophysiological changes,comorbidities,and polypharmacy,older adults may respond differently to drugs than younger individuals.This necessitates targeted drug development and adjusted dosages.However,older adults,particularly those over 80 years of age,are often underrepresented in clinical trials.This lack of research data hinders the safe and effective use of medications in this age group.New drug development and clinical research hold immense potential for improving the well-being of older adults.To achieve this,strong collaboration between governments,pharmaceutical companies,and research institutions is essential.In-depth studies on how medications interact with the aging body are crucial.Furthermore,establishing a robust scientific evaluation system,informed by both policy and scientific advancements,is paramount to ensure the safety and efficacy of medications for older adults.This article explores key considerations for new drug development and clinical research specific to this growing demographic,taking into account both domestic and international regulatory developments.
the older populationinnovative drugdrug regulationclinical designfrailtyaging-friendly
NETL
NSTL
万方数据
